ABC-06
ABC-06 was the first randomised trial to show that a second round of chemotherapy, FOLFOX, helps people with bile duct and gallbladder cancer live somewhat longer once gemcitabine and cisplatin have stopped working.
Overview
The UK ABC-06 trial randomised 162 patients with locally advanced or metastatic biliary tract cancer (cholangiocarcinoma, gallbladder or ampullary cancer) whose disease had progressed on first-line gemcitabine and cisplatin to active symptom control alone or with modified FOLFOX (oxaliplatin, folinic acid and fluorouracil). The primary endpoint was overall survival.
FOLFOX produced a modest but significant improvement in overall survival with acceptable toxicity, and gave biliary cancer its first evidence-based second-line chemotherapy. Targeted drugs for FGFR2 and IDH1 alterations and the NIFTY trial of liposomal irinotecan have since added other options.
Similar pages
not linked directly; found by shared links- TrialFIGHT-302
Shares Biliary tract cancer (all types), Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma) and the tag subtype-trials.
- TrialESOPEC
Shares Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU) and the tag subtype-trials.
- TrialFLOT4-AIO
Shares Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU) and the tag subtype-trials.
- TrialKEYNOTE-811
Shares Oxaliplatin, Fluorouracil (5-FU) and the tag subtype-trials.
- TrialTPExtreme (GORTEC 2014-01)
Shares Fluorouracil (5-FU) and the tag subtype-trials.
- TrialKEYNOTE-062
Shares Fluorouracil (5-FU) and the tag subtype-trials.
- TrialBILCAP
Shares Biliary tract cancer (all types), Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer, Intrahepatic cholangiocarcinoma.
- TrialABC-02
Shares Biliary tract cancer (all types), Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer, Intrahepatic cholangiocarcinoma.